Skip to main content

Peer Review reports

From: Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Original Submission
27 Sep 2022 Submitted Original manuscript
6 Oct 2022 Reviewed Reviewer Report - Jieqiong Liu
10 Oct 2022 Reviewed Reviewer Report
2 Nov 2022 Author responded Author comments - Jiong Wu
Resubmission - Version 2
2 Nov 2022 Submitted Manuscript version 2
4 Nov 2022 Reviewed Reviewer Report - Jieqiong Liu
17 Nov 2022 Reviewed Reviewer Report
6 Dec 2022 Author responded Author comments - Jiong Wu
Resubmission - Version 3
6 Dec 2022 Submitted Manuscript version 3
Publishing
12 Dec 2022 Editorially accepted
27 Dec 2022 Article published 10.1186/s12916-022-02708-3

You can find further information about peer review here.

Back to article page